Inovio Pharmaceuticals

Focus: Inovio Pharmaceuticals is a San Diego-based biotech company specializing in DNA vaccine technology and electroporation-based therapeutics across oncology, infectious diseases, neurology, and vaccines. The company operates a broad pipeline focused on precision immunotherapies rather than marketed revenue-generating products.

Oncology Neurology Infectious Diseases Vaccines

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Inovio Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Inovio Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

NKTR-214

Metastatic Castration-resistant Prostate Cancer

Phase 1

FVH1 - a DNA-based influenza vaccine

Influenza, Human

Phase 1

Clinical Trials (1)

Help build intelligence for Inovio Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Portfolio spans 30 pipeline programs with 2 Phase 3 programs (VGX-3100 in cervical dysplasia, MedPulser electroporation in head/neck cancer) offering near-term catalysts
Proprietary DNA vaccine + electroporation platform (CELLECTRA®) is differentiated technology with applications across oncology, infectious disease, and viral indications
Diverse therapeutic areas (HIV, HPV, Hepatitis C, Lassa Fever, cancer immunotherapy) provide exposure to multiple indications and regulatory pathways

Watch Out For

Zero active job openings listed and no employee count data signal potential hiring freeze or organizational constraint limiting career mobility
Heavy Phase 1/2 concentration (14 Phase 1, 11 Phase 2 programs) with minimal Phase 3 depth (2 programs) indicates long development runway before meaningful revenue catalysts
No revenue data, financials, or cash position information available—inability to assess financial stability or funding runway represents material career risk

Generated by Claude from Inovio Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NCT01587131DNA-based Influenza Vaccine in the Elderly

Phase 1

INO-3605

Healthy

Phase 1

Clinical Trials (1)

NCT01405885A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus

Phase 1

dMAb AZD5396

Healthy Volunteers

Phase 1

GLS-5300

Healthy

Phase 1

Clinical Trials (1)

NCT02670187Phase I, Open Label Dose Ranging Safety Study of GLS-5300 in Healthy Volunteers

Phase 1

INO-4201

Ebola Virus Disease

Phase 1

Clinical Trials (1)

NCT04906629INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees

Phase 1

INO-3106, INO-9012

Aerodigestive Precancerous Lesions and Malignancies

Phase 1

Clinical Trials (1)

NCT02241369Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies

Phase 1

INO-5401

BRCA1/2 Mutation

Phase 1

Clinical Trials (1)

NCT04367675INO 5401 Vaccination in BRCA1/2 Mutation Carriers

Phase 1

INO-4500

Lassa Fever

Phase 1

Clinical Trials (1)

NCT04093076Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana

Phase 1

VGX-3400

Healthy

Phase 1

Clinical Trials (1)

NCT01184976Study Of VGX-3400, H5N1 Avian Flu Virus Plasmid DNA With Electroporation Device In Healthy Adult Males

Phase 1

INO-4500

Lassa Fever

Phase 1

Clinical Trials (1)

NCT03805984Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers

Phase 1

GLS-5700

Healthy

Phase 1

Clinical Trials (1)

NCT02887482GLS-5700 in Dengue Virus Seropositive Adults

Phase 1

Electroporation-Mediated Plasmid DNA Vaccine Therapy

Chronic Hepatitis

Phase 1

Clinical Trials (1)

NCT02772003DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection

Phase 1

VGX-3100

Papillomavirus Infections

Phase 1

Clinical Trials (1)

NCT00685412Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3

Phase 1

INO-A002

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT03831503A Study of INO-A002 in Healthy Dengue Virus-naive Adults

Phase 1

INO-4800

Coronavirus Infection

Phase 1

Clinical Trials (1)

NCT04336410Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers

Phase 1

GLS-5700

Healthy

Phase 1

Clinical Trials (1)

NCT02809443GLS-5700 in Dengue Virus-Naïve Adults

Phase 1

GLS-6150

HCV Infection

Phase 1

Clinical Trials (1)

NCT03674125Evaluation of Safety, Tolerability, and Immunogenicity Study of GLS-6150 in Healthy Volunteers and in Persons Previously Treated for Hepatitis C Virus Infection

Phase 1

INO-4201

Ebola Vaccine

Phase 1

Clinical Trials (1)

NCT02464670Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers

Phase 1

sD-NP-GT8 DNA

HIV Infections

Phase 1

VGX-3400X

Healthy

Phase 1

Clinical Trials (1)

NCT01142362Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults

Phase 1

INO-3401 + EP

Healthy

Phase 1

Clinical Trials (1)

NCT01403155A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001

Phase 1

INO-4800

Coronavirus Infection

Phase 1

Clinical Trials (1)

NCT05430958Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers

Phase 1

V930

Healthy

Phase 1

VGX-3100

Human Papillomavirus (HPV)

Phase 1

Clinical Trials (1)

NCT01188850Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100

Phase 1

PENNVAX-B

HIV-1 Infection

Phase 1

Clinical Trials (1)

NCT01082692Study of PENNVAX™-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult Participants

Phase 1

2mg INO-5150 and electroporation device CELLECTRA®-5P

Prostate Cancer

Phase 1

Clinical Trials (1)

NCT02514213Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer

Phase 1

INO-1400

Breast Cancer

Phase 1

Clinical Trials (1)

NCT02960594hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse

Phase 1

INO-1800

Hepatitis B

Phase 1

Clinical Trials (1)

NCT02431312Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects

Phase 1

VGX-6150

Hepatitis C, Chronic

Phase 1

Clinical Trials (1)

NCT02027116Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection

Phase 1

INO-4800

Coronavirus Infection

Phase 1/2

Clinical Trials (1)

NCT04447781Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19

Phase 1/2

PENNVAX-GP

HIV-1-infection

Phase 1/2

Clinical Trials (1)

NCT03606213Therapeutic Vaccination in Treated HIV Disease

Phase 1/2

CHRONVAC-C®

Chronic Hepatitis C Virus Infection

Phase 1/2

Clinical Trials (1)

NCT00563173Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV Patients

Phase 1/2

INO-3112

Head and Neck Squamous Cell Cancer

Phase 1/2

Clinical Trials (1)

NCT02163057Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma

Phase 1/2

INO-5401

Glioblastoma

Phase 1/2

Clinical Trials (1)

NCT03491683INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

Phase 1/2

INO-3107

Respiratory Papillomatosis

Phase 1/2

Clinical Trials (1)

NCT04398433INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)

Phase 1/2

INO-3112

Cervical Cancer

Phase 1/2

Clinical Trials (1)

NCT02172911A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer

Phase 1/2

GLS-5300

Healthy

Phase 1/2

Clinical Trials (1)

NCT03721718Evaluate the Safety, Tolerability and Immunogenicity Study of GLS-5300 in Healthy Volunteers

Phase 1/2

INO-5401

Urothelial Carcinoma

Phase 1/2

Clinical Trials (1)

NCT03502785INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

Phase 1/2

INO-3112 vaccine

Uterine Cervical Neoplasms

Phase 2

Clinical Trials (1)

NCT02501278A Phase II Clinical Trial of Chemo-radiotherapy in Combination With INO-3112 in Patients With Locally Advanced Cervical Cancer

Phase 2

p.DOM-WT1-37 DNA Vaccine and p.DOM-WT1-126 DNA Vaccine

Leukaemia (Acute)

Phase 2

Clinical Trials (1)

NCT01334060WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation

Phase 2

Electroporation

Anal Intraepithelial Neoplasia

Phase 2

Clinical Trials (1)

NCT03603808VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions

Phase 2

INO-4700

Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

Phase 2

Clinical Trials (1)

NCT04588428Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers

Phase 2

VGX 3100

Cervical Intraepithelial Neoplasia

Phase 2

Clinical Trials (1)

NCT01304524A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3

Phase 2

VGX-3100

Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)

Phase 2

Clinical Trials (1)

NCT03180684Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)

Phase 2

VGX-3100

Anal Neoplasm

Phase 2

Clinical Trials (1)

NCT03499795VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2

Phase 2

ChronVac-C + SOC

Chronic Hepatitis C

Phase 2

Clinical Trials (1)

NCT01335711CHRONVAC-C Study Followed by Standard of Care in Chronic Hepatitis C Virus (HCV) Subjects

Phase 2

INO-4800

Coronavirus Infection

Phase 2/3

Clinical Trials (1)

NCT04642638Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure